Senzime AB (publ) Stock Forecast for 2023 - 2025 - 2030
Updated on 05/03/2024
Senzime AB (publ) Stock Forecast and Price Target
If the average 2024 price target of kr13.50 recently set by prominent experts for Senzime AB (publ) is met, there would be a potential upside of approximately 82.93% from the last closing price in May, 2024. The high estimate is kr13.50, and the low is kr13.50. If you want to buy SEZI stock, it might be a good idea to look at its competitors too.
82.93% Upside
Senzime AB (publ) Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Senzime AB (publ)'s Price has grown from kr0.00 to kr0.00 – a 100.00% increase. Next year, analysts are expecting Fair Value to reach kr7.84 – an increase of 100.00%. Over the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GETI B Stock Forecast | Getinge AB | Outperform |
18
|
kr231.90 | Buy/Sell | kr226.10 | -1.68% |
| EKTA B Stock Forecast | Elekta AB (publ) | Hold |
18
|
kr77.00 | Buy/Sell | kr83.00 | 1.30% |
| ALIF B Stock Forecast | AddLife AB (publ) | Buy |
18
|
kr100.00 | Buy/Sell | kr111.00 | 37.00% |
| SUS Stock Forecast | Surgical Science Sweden AB (pu... | Outperform |
14
|
kr155.10 | Buy/Sell | kr230.33 | 45.07% |
| CEVI Stock Forecast | CellaVision AB (publ) | Outperform |
16
|
kr227.50 | Buy/Sell | kr191.75 | 7.69% |
Senzime AB (publ) Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Senzime AB (publ)'s Revenue has grown from kr9.34M to kr35.75M – a 282.76% increase. Next year, analysts are expecting Revenue to reach kr90.80M – an increase of 153.99%. Over the next seven years, the forecast is for Revenue to grow by 271.58%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BICO Stock Forecast | BICO Group AB (publ) | Buy |
7
|
kr47.46 | Buy/Sell | kr135.00 | 179.18% |
| HANDI Stock Forecast | Handicare Group AB (publ) | - |
16
|
kr0.00 | Buy/Sell | kr4.92 | 0.00% |
| CRAD B Stock Forecast | C-Rad AB (publ) | Outperform |
11
|
kr39.15 | Buy/Sell | kr65.50 | 48.15% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SYNT Stock Forecast | SyntheticMR AB (publ) | Outperform |
14
|
kr27.70 | Buy/Sell | kr30.00 | 8.30% |
| MNTC Stock Forecast | Mentice AB (publ) | Outperform |
6
|
kr36.60 | Buy/Sell | kr67.17 | 50.27% |
| PAX Stock Forecast | Paxman AB (publ) |
8
|
kr36.50 | Buy/Sell | kr84.00 | 119.18% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SPEC Stock Forecast | SpectraCure AB (publ) | - |
0
|
kr2.80 | Buy/Sell | kr0.00 | -100.00% |
| QLINEA Stock Forecast | Q-linea AB (publ) |
6
|
kr2.56 | Buy/Sell | kr10.00 | 232.03% | |
| LUMITO Stock Forecast | Lumito AB (publ) | - |
0
|
kr1.75 | Buy/Sell | kr0.00 | -100.00% |
Senzime AB (publ) EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Senzime AB (publ)'s EBITDA has grown, rising from kr-46.89M to kr-116.79M – a growth of 149.07%. According to the 1 analysts polled, in the next year, Senzime AB (publ)'s EBITDA will fall by 43.83%, reaching kr-65.60M. For the next seven years, the forecast is for EBITDA to grow by 781.16%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ACARIX Stock Forecast | Acarix AB (publ) |
0
|
kr0.26 | Buy/Sell | kr0.65 | 130.77% | |
| MEDF Stock Forecast | Medfield Diagnostics AB (publ) | - |
0
|
kr0.29 | Buy/Sell | kr0.00 | -100.00% |
| OM:IRRAS Stock Forecast | IRRAS AB (publ) |
0
|
kr0.16 | Buy/Sell | kr2.58 | 3025.00% |
Senzime AB (publ) EBIT Forecast for 2023 - 2025 - 2030
Senzime AB (publ)'s EBIT has grown In the last three years, rising from kr-47.23M to kr-137.36M – a growth of 190.83%. For the next year, 1 analysts project Senzime AB (publ)'s EBIT to drop by 37.39%, reaching kr-86.00M. By 2030, professionals believe that Senzime AB (publ)'s EBIT will decrease by 140.37%, reaching kr55.45M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CMH Stock Forecast | Chordate Medical Holding AB (p... | - |
0
|
kr0.10 | Buy/Sell | kr0.00 | -100.00% |
| ARCOMA Stock Forecast | Arcoma AB |
0
|
kr13.30 | Buy/Sell | kr12.50 | 12.78% | |
| REDS Stock Forecast | Redsense Medical AB (publ) | - |
-10
|
kr5.46 | Buy/Sell | kr0.00 | -100.00% |
Senzime AB (publ) EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Senzime AB (publ)'s EPS has grown from kr-1.31 to kr0.00 – a 100.00% increase. Next year, analysts are expecting EPS to reach kr-0.84 – an increase of 100.00%. Over the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| RNBS Stock Forecast | RNB Retail and Brands AB (publ... | - |
0
|
kr49.00 | Buy/Sell | kr250.00 | -100.00% |
| CLS B Stock Forecast | Clinical Laserthermia Systems ... |
0
|
kr16.36 | Buy/Sell | kr0.40 | 223.96% | |
| HEART Stock Forecast | Scandinavian Real Heart AB (Pu... | - |
0
|
kr0.57 | Buy/Sell | kr0.00 | -100.00% |
.jpg)